Axa S.A. Editas Medicine, Inc. Transaction History

Axa S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $72,660 - $97,755	-10,500 Reduced 9.95%	95,000 $741,000
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $36,888 - $66,526	-5,800 Reduced 5.21%	105,500 $868,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $926,016 - $1.47 Million	111,300 New	111,300 $987,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $278,775 - $425,985	-10,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $412,335 - $765,870	10,500 New	10,500 $431,000

240

56.5M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.